MA33052B1 - Variants de liaison anti-albumine sérique améliorés - Google Patents
Variants de liaison anti-albumine sérique améliorésInfo
- Publication number
- MA33052B1 MA33052B1 MA34105A MA34105A MA33052B1 MA 33052 B1 MA33052 B1 MA 33052B1 MA 34105 A MA34105 A MA 34105A MA 34105 A MA34105 A MA 34105A MA 33052 B1 MA33052 B1 MA 33052B1
- Authority
- MA
- Morocco
- Prior art keywords
- serum albumin
- contrasts
- albumin enhancer
- antagonist
- antagonist serum
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
L'invention porte sur des variants améliorés du domaine variable unique DOM7h-14 de l'immunoglobuline anti-albumine sérique, ainsi que des ligands et des conjugués de médicaments contenant de tels variants, des compositions, des acides nucléiques, des vecteurs et des hôtes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15374609P | 2009-02-19 | 2009-02-19 | |
US16399009P | 2009-03-27 | 2009-03-27 | |
PCT/EP2010/052007 WO2010094722A2 (fr) | 2009-02-19 | 2010-02-17 | Variants de liaison anti-albumine sérique améliorés |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33052B1 true MA33052B1 (fr) | 2012-02-01 |
Family
ID=42306619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34105A MA33052B1 (fr) | 2009-02-19 | 2010-02-17 | Variants de liaison anti-albumine sérique améliorés |
Country Status (23)
Country | Link |
---|---|
US (2) | US9175071B2 (fr) |
EP (1) | EP2398825B1 (fr) |
JP (1) | JP5766616B2 (fr) |
KR (1) | KR101820968B1 (fr) |
CN (2) | CN105061593B (fr) |
AR (1) | AR075506A1 (fr) |
AU (2) | AU2010215481C1 (fr) |
BR (1) | BRPI1008705B1 (fr) |
CA (1) | CA2753130C (fr) |
CL (1) | CL2011002023A1 (fr) |
CO (1) | CO6450689A2 (fr) |
DO (1) | DOP2011000269A (fr) |
EA (1) | EA027866B1 (fr) |
ES (1) | ES2654929T3 (fr) |
IL (1) | IL214481A0 (fr) |
MA (1) | MA33052B1 (fr) |
MX (1) | MX2011008752A (fr) |
PE (1) | PE20120170A1 (fr) |
SG (1) | SG173488A1 (fr) |
TW (1) | TW201042041A (fr) |
UY (1) | UY32452A (fr) |
WO (1) | WO2010094722A2 (fr) |
ZA (1) | ZA201105658B (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG194383A1 (en) * | 2008-12-05 | 2013-11-29 | Glaxo Group Ltd | Methods for selecting protease resistant polypeptides |
EP3330287B1 (fr) | 2009-02-19 | 2019-12-18 | Glaxo Group Limited | Variants de liaison anti-albumine sérique améliorés |
US8779103B2 (en) * | 2009-03-27 | 2014-07-15 | Glaxo Group Limited | Drug fusions and conjugates |
AU2010303112A1 (en) * | 2009-09-30 | 2012-04-26 | Glaxo Group Limited | Drug fusions and conjugates with extended half life |
JP2013529080A (ja) * | 2010-05-20 | 2013-07-18 | グラクソ グループ リミテッド | 改良された抗血清アルブミン結合変異体 |
US9012609B2 (en) | 2010-08-13 | 2015-04-21 | Glaxosmithkline Intellectual Property Development Limited | Anti-serum albumin binding variants |
BR112013007442A2 (pt) * | 2010-09-28 | 2019-09-24 | Amylin Pharmaceuticals Llc | polipeptídeos construídos tendo duração de ação realçada |
EP2646467A2 (fr) | 2010-12-01 | 2013-10-09 | Glaxo Group Limited | Domaines variables améliorés à liaison unique d'anti-albumine sérique |
US20130310281A1 (en) | 2011-02-02 | 2013-11-21 | Glaxo Group Limited | Novel antigen binding proteins |
MA45051A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant la relaxine |
CN110177802A (zh) | 2016-12-09 | 2019-08-27 | 格利克尼克股份有限公司 | 多聚化stradomer GL-2045的制造优化 |
IL266988B1 (en) | 2016-12-09 | 2024-07-01 | Gliknik Inc | Methods for the treatment of inflammatory disorders with multivalent FC compounds |
CN118403180A (zh) | 2017-02-16 | 2024-07-30 | 索纳特生物疗法公司 | 白蛋白结合结构域融合蛋白 |
IL271127B1 (en) * | 2017-06-05 | 2024-06-01 | Numab Therapeutics AG | New anti-HSA antibodies |
WO2018224439A1 (fr) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Nouveaux anticorps anti-hsa |
WO2019204925A1 (fr) | 2018-04-24 | 2019-10-31 | National Research Council Of Canada | Anticorps de liaison à l'albumine sérique pour extension de demi-vie réglable de produits biologiques |
KR102204315B1 (ko) * | 2018-11-16 | 2021-01-18 | 한국세라믹기술원 | 인간 혈청 알부민에 특이적으로 결합하는 어피바디 및 그의 용도 |
WO2024097639A1 (fr) * | 2022-10-31 | 2024-05-10 | Modernatx, Inc. | Anticorps se liant à hsa et protéines de liaison et leurs utilisations |
WO2024170756A1 (fr) | 2023-02-17 | 2024-08-22 | Ablynx N.V. | Polypeptides se liant au récepteur fc néonatal |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19713272A1 (de) | 1997-03-29 | 1998-10-08 | Junghans Uhren Gmbh | Zeitzonen-Uhr |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
CN1678634A (zh) | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
SI1737962T1 (sl) | 2004-03-24 | 2011-01-31 | Domantis Ltd | Univerzalni signalni peptid GAS1 |
EP1784427A2 (fr) | 2004-06-01 | 2007-05-16 | Domantis Limited | Anticorps de fusion bispecifiqus avec une demi-vie augmentee |
CN101111522A (zh) | 2004-12-02 | 2008-01-23 | 杜门蒂斯有限公司 | 由于和功能域抗体缀合而具有提高的血清半衰期的plad功能域肽 |
CN101128487B (zh) | 2004-12-02 | 2012-10-10 | 杜门蒂斯有限公司 | 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体 |
CA2640066A1 (fr) | 2006-01-24 | 2007-08-02 | Roland Beckmann | Proteines de fusion contenant des jonctions naturelles |
GB0621513D0 (en) | 2006-10-30 | 2006-12-06 | Domantis Ltd | Novel polypeptides and uses thereof |
GB0724331D0 (en) * | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
CA2688434A1 (fr) | 2007-06-06 | 2008-12-11 | Domantis Limited | Polypeptides, domaines variables d'anticorps et antagonistes |
US20110236380A1 (en) | 2008-11-26 | 2011-09-29 | De Wildt Rudolf M T | Ligands that bind il-13 |
-
2010
- 2010-02-17 PE PE2011001426A patent/PE20120170A1/es not_active Application Discontinuation
- 2010-02-17 US US13/202,355 patent/US9175071B2/en active Active
- 2010-02-17 SG SG2011055340A patent/SG173488A1/en unknown
- 2010-02-17 KR KR1020117021612A patent/KR101820968B1/ko active IP Right Grant
- 2010-02-17 MX MX2011008752A patent/MX2011008752A/es not_active Application Discontinuation
- 2010-02-17 CN CN201510340467.5A patent/CN105061593B/zh active Active
- 2010-02-17 ES ES10706186.3T patent/ES2654929T3/es active Active
- 2010-02-17 EP EP10706186.3A patent/EP2398825B1/fr active Active
- 2010-02-17 MA MA34105A patent/MA33052B1/fr unknown
- 2010-02-17 JP JP2011550553A patent/JP5766616B2/ja active Active
- 2010-02-17 AU AU2010215481A patent/AU2010215481C1/en not_active Ceased
- 2010-02-17 CN CN201080017229.6A patent/CN102405232B/zh not_active Expired - Fee Related
- 2010-02-17 EA EA201171067A patent/EA027866B1/ru not_active IP Right Cessation
- 2010-02-17 AR ARP100100461A patent/AR075506A1/es not_active Application Discontinuation
- 2010-02-17 CA CA2753130A patent/CA2753130C/fr active Active
- 2010-02-17 UY UY0001032452A patent/UY32452A/es unknown
- 2010-02-17 WO PCT/EP2010/052007 patent/WO2010094722A2/fr active Application Filing
- 2010-02-17 BR BRPI1008705-2A patent/BRPI1008705B1/pt active IP Right Grant
- 2010-02-22 TW TW099105015A patent/TW201042041A/zh unknown
-
2011
- 2011-08-01 ZA ZA2011/05658A patent/ZA201105658B/en unknown
- 2011-08-04 IL IL214481A patent/IL214481A0/en unknown
- 2011-08-18 CL CL2011002023A patent/CL2011002023A1/es unknown
- 2011-08-19 DO DO2011000269A patent/DOP2011000269A/es unknown
- 2011-08-30 CO CO11111117A patent/CO6450689A2/es not_active Application Discontinuation
-
2014
- 2014-05-20 AU AU2014202764A patent/AU2014202764B2/en not_active Ceased
-
2015
- 2015-09-23 US US14/862,818 patent/US9751935B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33052B1 (fr) | Variants de liaison anti-albumine sérique améliorés | |
MA33051B1 (fr) | Variants de liaison anti-albumine serique ameliores | |
CY1119454T1 (el) | Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος | |
IN2012DN00640A (fr) | ||
MA35659B1 (fr) | Protéine de liaison à un antigène et son utilisation comme produit d'adressage pour le traitement du cancer | |
CY1116578T1 (el) | Αναστολεις της bromodomain και χρησεις αυτων | |
MX2012013406A (es) | Variantes de union mejoradas anti-albumina serica. | |
MA37840A3 (fr) | Immunoconjugués comprenant des anticorps anti-cd79b | |
UA106194C2 (ru) | Диагностика и лечение рака с применением антитела к ereg | |
SG10201405377XA (en) | Compositions and methods for antibodies targeting complement protein c5 | |
EA201170441A1 (ru) | Терапевтические противовирусные пептиды | |
MX2010005871A (es) | Anticuerpos al antigeno de pcrv de pseudomonas aeruginosa. | |
TR201903026T4 (tr) | S100a4 anti̇korlari ve bunlarin terapöti̇k kullanimlari. | |
CY1115960T1 (el) | Θεραπευτικη αγωγη ογκων χρησιμοποιωντας ειδικο αντισωμα anti-l1 | |
MA39378A1 (fr) | Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer | |
ATE472998T1 (de) | Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis | |
MA35281B1 (fr) | Dosage et administration d'anticorps anti-erbb3 en combinaison avec le paclitaxel pour le traitement de cancers gynécologiques | |
EA201390116A1 (ru) | Улучшенные связывающие варианты против сывороточного альбумина | |
MA34487B1 (fr) | Compositions d'anticorps anti-vegfr-3. | |
CY1116251T1 (el) | Συστηματα michael ως αναστολεις τρανσγλουταμινασων | |
MA37838A1 (fr) | Immunoconjugués comprenant des anticorps anti-cd22 | |
CR20110473A (es) | Variantes de union a anti-albúmina de suero mejoradas. |